Cemiplimab in advanced cutaneous squamous cell carcinoma: the UK experience from the Named Patient Scheme

Affiliations

¹ University Hospitals Bristol & Weston NHS Foundation Trust, Bristol, UK.
² University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
³ University Hospitals Plymouth NHS Trust, Plymouth, UK.
⁴ Royal Cornwall Hospitals NHS Trust, Truro, UK.
⁵ Portsmouth Hospitals NHS Trust, Portsmouth, UK.
⁶ The Christie NHS Foundation Trust, Manchester, UK.
⁷ Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK.
⁸ East Suffolk and North Essex NHS Foundation Trust, Colchester, UK.
⁹ Taunton and Somerset NHS Foundation Trust, Taunton, UK.
¹⁰ Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
¹¹ NHS Greater Glasgow and Clyde, Glasgow, UK.
¹² Hull University Teaching Hospitals NHS Trust, Hull, UK.
¹³ University Hospitals of Leicester NHS Trust, Leicester, UK.
¹⁴ NHS Lothian, Edinburgh, UK.
¹⁵ School of Cancer and Pharmaceutical Studies, King's College London, London, UK.
¹⁶ St George's University Hospitals NHS Foundation Trust, London, UK.
¹⁷ Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

A Challapalli et al. J Eur Acad Dermatol Venereol. 2022 Jul.

. 2022 Jul;36(7):e590-e592.

doi: 10.1111/jdv.18082. Epub 2022 Mar 24.

¹ University Hospitals Bristol & Weston NHS Foundation Trust, Bristol, UK.
² University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
³ University Hospitals Plymouth NHS Trust, Plymouth, UK.
⁴ Royal Cornwall Hospitals NHS Trust, Truro, UK.
⁵ Portsmouth Hospitals NHS Trust, Portsmouth, UK.
⁶ The Christie NHS Foundation Trust, Manchester, UK.
⁷ Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK.
⁸ East Suffolk and North Essex NHS Foundation Trust, Colchester, UK.
⁹ Taunton and Somerset NHS Foundation Trust, Taunton, UK.
¹⁰ Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
¹¹ NHS Greater Glasgow and Clyde, Glasgow, UK.
¹² Hull University Teaching Hospitals NHS Trust, Hull, UK.
¹³ University Hospitals of Leicester NHS Trust, Leicester, UK.
¹⁴ NHS Lothian, Edinburgh, UK.
¹⁵ School of Cancer and Pharmaceutical Studies, King's College London, London, UK.
¹⁶ St George's University Hospitals NHS Foundation Trust, London, UK.
¹⁷ Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

No abstract available

References

1. Stratigos AJ, Garbe C, Dessinioti C et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. Eur J Cancer 2020; 128: 60-82.
1. Migden MR, Rischin D, Schmults CD et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med 2018; 379: 341-351.
1. Rischin D, Khushalani N, Schmults C et al. Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Follow-Up at 43 Months. . 2021: EADO Abstract P-236.
1. Rischin D, Khushalani NI, Schmults CD et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer 2021; 9: e002757.
1. Baggi A, Quaglino P, Rubatto M et al. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. Eur J Cancer 2021; 157: 250-258.